Statement of Principles concerning Discoid Lupus Erythematosus (Balance of Probabilities) (No. 50 of 2025)

The SoP is organised around a limited set of legal‑medical concepts that direct how causation is established in claims. The core concepts and their statutory anchors are:

• Legal definition of the condition: "Discoid lupus erythematosus" is defined in statutory text at s7(2). The instrument narrows the clinical scope by listing excluded forms of lupus (s7(2)(b)(i)-(viii)). The SoP therefore sets a definitional boundary for which clinical presentations count for claim purposes, notwithstanding the ICD code reference (s7(3)).
• Death from the condition: "Death from discoid lupus erythematosus" is defined to include death from a terminal event or condition that was contributed to by the person’s DLE (s7(4)). The Schedule gives examples of terminal events such as pneumonia, respiratory failure, cardiac arrest and cessation of brain function (Schedule 1).
• Standard of proof and evidential basis: The RMA states the decision was made on the sound medical‑scientific evidence available and that it is "more probable than not" that DLE can be related to relevant service (s8). The phrase "more probable than not" references the civil standard of proof, and the SoP is intended to be used on that balance of probabilities in adjudicating claims (s8).
• Required factors: Section 9 lists the discrete factors that, if present and related to relevant service, are sufficient to establish the connection. These factors are:
  • Sunlight or ultraviolet exposure sufficient to induce erythema (sunburn) occurring at least 24 hours but no more than 30 days before clinical onset or clinical worsening (s9(1));
  • Taking specified systemic medications at the time of onset/worsening: fluorouracils (including 5‑fluorouracil, capecitabine and tegafur), excluding topical agents, and tumour necrosis factor‑alpha inhibitors (s9(2)(a)-(b));
  • Taking a medication associated with DLE that developed during therapy and improved within 3 months of discontinuing, where treatment had continued for at least the 3 days before onset/worsening (s9(3));
  • Smoking of at least 10 pack‑years where smoking had not ceased before onset/worsening (s9(4); Schedule 1 definition);
  • Inability to obtain appropriate clinical management for DLE before clinical worsening (s9(5)).
• Relationship to service: Section 10(1) requires that the existence of any of the factors in s9 be related to the person's relevant service. Section 10(2) limits the "clinical worsening" aspects of the factors to situations where the DLE was suffered or contracted before or during, but did not arise out of, relevant service; in those cases the factor must materially contribute to, or aggravate, the ongoing condition (s10(2)).
• Cross‑reference to other SoPs: Section 11 provides that if a factor in s9 refers to an injury or disease covered by another SoP, the factors in that other SoP apply according to its terms as in force from time to time (s11).
• Definitions: Schedule 1 supplies definitions that are operative across the instrument including "relevant service", MRCA, VEA, "one pack‑year" and "terminal event" (Schedule 1).

Collectively these concepts create a structured, evidence‑based rulebook for linking DLE and death from DLE to relevant service, with particular temporal and substance‑specific thresholds that must be met.

The SoP directly affects claimants, clinicians who provide evidence for claims, and decision‑makers applying the VEA and MRCA. The instrument itself says it applies to "a claim to which section 120B of the VEA or section 339 of the MRCA applies" (s5). That description limits the universe of affected persons to those lodging or litigating entitlement claims under those claim provisions in the respective Acts. Practically this will include:

• Veterans and members of the Forces who seek compensation, rehabilitation or other benefits where DLE or death from DLE is asserted to be connected with service. The Schedule defines "relevant service" as eligible war service, defence service (other than hazardous service and British nuclear test defence service) under the VEA, or peacetime service under the MRCA (Schedule 1).
• Medical practitioners and specialists who provide expert reports, diagnoses, timelines of clinical onset or worsening, medication histories, smoking histories, treatment response and records of attempted or failed clinical management. The SoP sets out specific factual thresholds that clinicians must speak to in reports, for example dates of exposure, evidence of erythema, timing and duration of medications, response to cessation of medications, and smoking pack‑year quantification (s9; Schedule 1).
• Administrative decision‑makers within the Department of Veterans' Affairs and adjudicative bodies that assess entitlement under the relevant Acts, because the SoP forms the medical standard applied to causation questions in claims under s120B (VEA) and s339 (MRCA) (s5). The RMA has made the SoP under s196B(3) of the VEA (s3), which is the statutory pathway for the RMA to determine SoPs used in adjudication.
• Legal representatives and advocates who prepare submissions and arguments for claims and appeals, because the SoP identifies precise evidentiary conditions that must be proven on the balance of probabilities. The instrument’s definitions and temporal windows constrain how practitioners frame causation arguments (s7, s9, s10).
• Parties involved in death benefit claims where DLE contributed to a terminal event. The SoP explicitly includes death from a terminal event or condition contributed to by DLE (s7(4)), and the Schedule lists examples of terminal events (Schedule 1).

The SoP does not itself create or specify monetary entitlements, investigative powers, or penalty regimes; it is a medico‑legal standard used in claims processes. It changes the evidentiary and definitional landscape for the specific condition of DLE for the set of claimants who rely on the VEA/MRCA provisions referenced (s5).

The SoP does not impose statutory duties in the sense of criminal or civil offences. Instead, it functions as a ruleset about what medical and factual links must be established to succeed in a claim. Rights and procedural duties flow from the underlying Acts and the claim processes that use the SoP; the instrument itself sets the parameters decision‑makers must apply. Key operative points are:

• Right to have the SoP applied to a claim: The instrument is declared to "apply to a claim to which section 120B of the VEA or section 339 of the MRCA applies" (s5). Claimants whose claims fall under those sections are entitled to have medical causation assessed using this SoP as the relevant medico‑scientific standard.
• Duty to connect factors to relevant service: Section 10(1) requires that any factor in s9 relied upon must be related to the person's relevant service. That places the evidential onus on claimants to show a link between the identified factor and the service period or activities that constitute relevant service under the Schedule definition.
• Burden to establish temporal and substance thresholds: The SoP identifies precise thresholds that must be proven on the balance of probabilities. Examples:
  • For ultraviolet/sun exposure, evidence that exposure produced erythema (sunburn) occurring at least 24 hours but no more than 30 days before clinical onset or worsening (s9(1)).
  • For medication associations, documentary proof that the claimant was taking specified systemic fluorouracils (5‑fluorouracil, capecitabine, tegafur) excluding topical agents, or tumour necrosis factor‑alpha inhibitors, at the time of clinical onset or worsening (s9(2)(a)-(b)).
  • For medication‑associated DLE, proof that the DLE developed during therapy and improved within 3 months of discontinuing therapy, where treatment had continued for at least 3 days before onset (s9(3)).
  • For smoking, evidence that smoking had not ceased before onset or worsening and that the person had smoked at least 10 pack‑years (s9(4); Schedule 1).
  • For clinical management failure, evidence of inability to obtain appropriate clinical management before clinical worsening (s9(5)).
• Right to have cross‑referenced SoPs applied: If a factor in s9 refers to an injury or disease covered by another SoP, then the rules in that other SoP apply according to its terms as in force from time to time (s11). This creates a right for claimants to have the relevant interconnected SoP considered.
• Right to rely on the RMA’s stated standard: The RMA records that it has determined the factors on the sound medical‑scientific evidence available and finds it "more probable than not" that DLE can be related to relevant service (s8). Parties can cite the SoP and its stated standard as the authoritative medico‑scientific formulation used by the RMA.
• Duty to observe the definitional limits: The SoP excludes a number of lupus subtypes from the statutory meaning of DLE at s7(2)(b). Claimants and clinicians must ensure the clinical presentation matches the statutory definition, not merely an ICD code, because s7(3) expressly states the legal meaning is that in s7(2).

The SoP does not specify procedural duties such as time limits for lodging claims, evidence production processes, or penalties for false claims; those procedural duties remain governed by the primary Acts and associated regulations and administrative practice.

The instrument itself contains no penalty or offence provisions and does not create enforcement powers. It is a statutory medical determination made under s196B(3) of the VEA (s3) that provides the medical framework decision‑makers must apply when adjudicating claims under s120B of the VEA and s339 of the MRCA (s5). Consequences in practice are therefore indirect and procedural rather than punitive within this instrument:

• No express sanctions: The SoP does not create criminal, civil or administrative penalties for non‑compliance; it does not, for example, prescribe fines, imprisonment, debarment or regulatory sanctions in this instrument text.
• Enforcement through claim processes: The practical effect of the SoP is enforced through the administrative and adjudicative processes set out in the primary legislation. Decisions on entitlement, benefit payments, liability for rehabilitation or death benefits will be made in light of the SoP where it applies. Section 5 ties the SoP to specific claim provisions in the VEA and MRCA, but the instrument itself leaves the enforcement mechanism, review rights, appeals and any sanctions for false statements to the relevant statutory frameworks outside this text.
• Evidentiary gatekeeper role: The SoP has an evidentiary effect in adjudication. If a claimant cannot establish one of the listed factors (s9) related to relevant service (s10), the SoP will not provide the required medico‑scientific link on which a favourable finding would be premised. In that sense the SoP functions as an enforcement‑adjacent instrument, because it establishes what must be proved to obtain entitlements.
• Interaction with other SoPs: Section 11 requires that, where a factor in s9 refers to an injury or disease covered by another SoP, the factors in that other SoP apply as in force. Enforcement of those aspects therefore depends on the contents of other SoPs and the claim processes that apply to them.

Practitioners and claimants should therefore treat the SoP as a determinative standard used by decision‑makers; the instrument itself does not police behaviour, but it materially affects the outcome of adjudicative and benefits processes administered under the VEA and MRCA. Any penalties, review rights or remedies arise from the primary Acts and their processes rather than from the SoP text.

This SoP is expressly created under the VEA and intended for use in adjudicating claims under specified provisions of the VEA and MRCA. The instrument provides several points of statutory interaction and limitation:

• Source of authority and application: The SoP is made under s196B(3) of the VEA (s3) and "applies to a claim to which section 120B of the VEA or section 339 of the MRCA applies" (s5). Those primary Acts define entitlement, procedural steps, review rights and remedies that govern how the SoP will be applied in practice. The SoP does not alter the substantive entitlements in those Acts; it supplies the medical criteria necessary to establish service connection for the specified condition.
• Cross‑references to other SoPs: Section 11 creates direct legal interaction between this SoP and other SoPs. If a factor in s9 refers to an injury or disease that itself has an SoP under s196B(3) of the VEA, the factors of that other SoP apply in accordance with its terms as in force from time to time. Thus where causation depends on an intermediary injury or disease, the legal assessment will follow the controlling SoP for that injury/disease (s11).
• ICD‑10‑AM code reference and limitation: Section 7(3) references ICD‑10‑AM code L93.0 for DLE and identifies the edition to which the reference is made (Tenth Edition, effective date 1 July 2017). However s7(2) makes clear the legal meaning of DLE for this SoP is the definition in the subsection, not merely the ICD code. The instrument therefore interacts with diagnostic coding systems but imposes an independent statutory definition.
• Relationship to MRCA and VEA definitions: Schedule 1 defines "relevant service" with respect to the VEA and MRCA categories (Schedule 1). The SoP must be read in conjunction with those primary Acts to determine whether an individual’s service qualifies as "relevant service" for claims (s10(1); Schedule 1).
• Procedural and evidentiary laws remain external: The SoP does not modify procedural rules that determine how evidence is adduced, assessed or weighed in administrative hearings, tribunals or courts. Those procedures are governed by the primary Acts, their regulations and relevant administrative law principles. The SoP supplies a medico‑scientific rule that decision‑makers must apply within those procedural frameworks.
• Death and terminal events: By including death from a terminal event contributed to by DLE (s7(4)) and by defining "terminal event" in the Schedule (Schedule 1), the SoP interacts with laws that determine death benefits, dependency and succession under the VEA and MRCA. The SoP supplies an evidentiary pathway to link DLE to terminal events that may be relevant under those other legal regimes.
• Repeal and continuity: The SoP repeals the prior SoP for DLE (No. 127 of 2015) (s4). Where prior adjudications or appeals turned on the earlier text, subsequent claims will be judged under the current SoP, subject to any transitional or saving rules in the primary Acts or administrative practice. The SoP does not itself set out transitional rules; those must be found in the VEA/MRCA or administrative decisions.

In short, the SoP functions as an authoritative medical standard that integrates with the statutory architectures of the VEA and MRCA, interacts with other SoPs where cross‑referenced, and relies on external procedural and evidentiary rules for implementation. Its definitions and temporal thresholds may alter how claims interact with other legal instruments by changing what medical facts must be proved.

The instrument is self‑evidently a replacement SoP and contains limited explicit amendment information in the text provided. The instrument:

• Repeals the previous Statement of Principles concerning discoid lupus erythematosus (No. 127 of 2015) (Federal Register of Legislation No. F2015L01681) made under subsection 196B(3) of the VEA (s4). That is the only express amendment or repeal recorded in the instrument text.
• Is dated 15 April 2025 and commences on 19 May 2025 (s2). The instrument records its date and the Chairperson of the RMA as signing on behalf of the RMA (cover page).
• Contains an express reference to the ICD‑10‑AM edition used for coding purposes (Tenth Edition effective 1 July 2017) (s7(3)). This indicates the instrument’s cross‑reference to external classification standards is fixed to that edition for the purpose of the SoP.

No other amendments, transitional arrangements, or savings provisions are included in the text provided. The instrument does not include a schedule of changes compared to the repealed 2015 SoP within the text supplied. To know what specifically changed between the 2015 SoP and this 2025 instrument one must compare the two texts directly; the present instrument records only that it repeals the prior instrument (s4).

Because section 11 states that factors in other SoPs apply "as in force from time to time", the legal effect of this SoP will change mechanically as other SoPs are amended; that creates an indirect amendment pathway by reference to the current force of other SoPs (s11).

Administratively, the RMA retains power to determine and thereby amend SoPs under the VEA framework. Any future amendments to this SoP would similarly be made under subsection 196B(3) of the VEA and would presumably be published and commence in the manner evidenced by the present instrument.

The instrument text supplied contains no litigation history. It records the RMA’s decision and date but does not reference any judicial or tribunal decisions, nor does it cite precedents or statutory interpretations arising from litigation. The SoP itself is an administrative medical determination and is intended for use in adjudication of claims under the VEA and MRCA; any litigation arising from decisions that apply this SoP would be recorded in the public law or veterans law cases, but no such cases or disputes are mentioned in the SoP text.

Practitioners should therefore treat the SoP as an authoritative administrative determination whose interaction with case law will be developed in the course of claims and appeals under the VEA and MRCA. To assess how courts or tribunals interpret or apply this SoP in practice, one must examine subsequent decisions of the Veterans’ Review Board, Administrative Appeals Tribunal, Federal Court, or appellate courts. None of that jurisprudence is contained in the instrument provided.

Because the SoP repeals a prior SoP (s4), there may be existing administrative or judicial determinations under the earlier instrument; however the current instrument does not summarise or reference any such determinations. Legal research beyond this instrument will be required to produce a litigation history of how DLE claims have been treated under either the old or new SoPs.

The SoP contains multiple technical thresholds and definitional limits that create potential pitfalls for claimants, clinicians and advisers. These are factual, procedural and interpretive traps that arise from the instrument’s text.

1. Narrow statutory definition of DLE: The legal definition in s7(2)(a) limits DLE to a specific chronic cutaneous form and expressly excludes a number of lupus subtypes and systemic lupus erythematosus (s7(2)(b)(i)-(viii)). Reliance on an ICD code alone is insufficient, because s7(3) clarifies the legal meaning is the definition in s7(2). A clinician’s diagnosis must map to the statutory description rather than merely an ICD label.

2. Time window for sun/UV exposure is tight: The sunlight/UV factor requires erythema (sunburn) occurring at least 24 hours but not more than 30 days before clinical onset or clinical worsening (s9(1)). Evidence must therefore show both an episode of sunburn and that it falls inside that narrow window. Claims based on more remote UV exposure, gradual cumulative exposure without an erythemal episode, or exposures outside the 24‑hour to 30‑day window will not meet this factor.

3. Medication coverage is specific and excludes topical fluorouracils: The medication factor lists systemic fluorouracils including 5‑fluorouracil, capecitabine and tegafur, but excludes topical agents (s9(2)(a)). This exclusion can remove cases where topical therapy is implicated from this factor’s coverage. The list also includes tumour necrosis factor‑alpha inhibitors (s9(2)(b)). Practitioners must document formulation, route and timing precisely.

4. Medication‑association requirement imposes two linked conditions plus duration: For the medication‑association factor, the SoP requires that the medication be associated with the development of DLE during therapy and that the DLE improve within 3 months of discontinuing therapy, and that treatment had continued for at least the 3 days before onset or worsening (s9(3)). This creates multiple evidentiary requirements: (a) temporal link between start of therapy and development, (b) documentation of improvement within a 3‑month post‑cessation window, and (c) evidence the medication was taken continuously for at least 3 days before onset. Lack of follow‑up showing improvement within 3 months may defeat the factor.

5. Smoking factor requires ongoing smoking and calculation of pack‑years: The smoking factor applies only "where smoking has not ceased before clinical onset or clinical worsening" and requires at least 10 pack‑years (s9(4)). The Schedule defines "one pack‑year" and provides conversions and a calculation example (Schedule 1). Claimants who stopped smoking before onset, or who cannot document cumulative exposure reaching 10 pack‑years, will not satisfy this factor.

6. "Inability to obtain appropriate clinical management" is open to interpretation: The SoP includes inability to obtain appropriate clinical management before clinical worsening as a factor (s9(5)), but it does not define "appropriate clinical management". Claimants will need documentary evidence such as appointment denials, referral delays, or system‑level barriers. The SoP leaves the content of "appropriate" to clinical assessment and adjudicators, which creates uncertainty.

7. Clinical worsening limitation for pre‑existing disease: Section 10(2) states that the clinical worsening aspects of the s9 factors apply only to material contribution to, or aggravation of, DLE where the DLE was suffered or contracted before or during (but did not arise out of) relevant service. In other words, if the DLE arose out of service, the clinical worsening pathway is not triggered; that is a specific statutory limit that affects how worsening is pleaded and proved.

8. Dependence on other SoPs for referred injuries: If a factor in s9 refers to another injury or disease covered by a separate SoP, section 11 requires application of that other SoP's factors "as in force from time to time" (s11). This can lead to shifting evidentiary standards if the referenced SoP is amended, and means claimants must track both instruments.

9. Death requires showing contribution to a terminal event: "Death from DLE" includes death from a terminal event or condition contributed to by DLE (s7(4)). Proving contribution to a terminal event (such as pneumonia or respiratory failure listed in Schedule 1) requires medical evidence linking DLE causally to the terminal event. The Schedule provides examples but does not limit the list, creating room for contest about proximate contribution.

10. Reliance on RMA’s "more probable than not" statement but administrative discretion remains: While the RMA states that the SoP is based on medical‑scientific evidence and is intended to be applied on the balance of probabilities (s8), the instrument does not remove administrative discretion in how evidence is assessed against the SoP within adjudicative processes.

These "gotchas" are textual and evidential constraints built into the SoP. Advisers should not assume broader or looser causal pathways than those the instrument expressly supplies.

Compliance in this context means assembling and presenting the medical, documentary and service evidence necessary to satisfy one or more of the s9 factors and to demonstrate that the factor(s) are related to relevant service as required by s10(1). Below are concrete steps, tied to the instrument’s text, for claimants, clinicians and advisers.

1. Confirm applicability of the SoP to the claim: Verify the claim is one that falls under s120B of the VEA or s339 of the MRCA so that the SoP applies (s5). Confirm the claimant’s service qualifies as "relevant service" under Schedule 1 (eligible war service, defence service other than hazardous or British nuclear test defence service, or peacetime service under the MRCA).

2. Establish the correct clinical diagnosis against the statutory definition: Obtain a detailed dermatology report that maps the clinical features to the statutory definition in s7(2)(a): chronic cutaneous lupus erythematosus presenting with erythematous, scaly plaques that often heal with scarring and atrophy, with a preference for the concha of the ear, head or neck. Specifically document that the presentation is not one of the excluded subtypes listed in s7(2)(b). Where diagnostic coding is used, include both the ICD code and a narrative linking the clinical picture to the statutory definition, because s7(3) emphasises the statutory meaning in s7(2).

3. For sunlight/UV exposure (s9(1)):

   • Obtain contemporaneous or retrospective medical evidence documenting an episode of erythema (sunburn).
   • Establish the date of the erythemal event and the date of clinical onset or clinical worsening of DLE. Evidence could include clinical notes, photographs, treatment records, or contemporaneous statements.
   • Show the erythema occurred at least 24 hours but not more than 30 days before onset/worsening. Claims that lack precise timing should seek corroborative evidence such as leave records, deployment entries, civilian attendance records, or witness statements.

4. For medication‑based factors (s9(2) and s9(3)):

   • Provide prescription records, pharmacy dispensing records, hospital chemotherapy charts, oncology or rheumatology clinic notes that specify the drug name, formulation, route, dosing and dates.
   • For the listed systemic fluorouracils (5‑fluorouracil, capecitabine, tegafur) ensure records show systemic use and not topical application; topical agents are expressly excluded (s9(2)(a)).
   • For tumour necrosis factor‑alpha inhibitors, supply the specific agent, dates and associated clinical context (s9(2)(b)).
   • For the medication‑association criteria (s9(3)), document (a) that DLE developed while on the medication, (b) that the medication was taken for at least the 3 days before onset or worsening, and (c) objective evidence of clinical improvement within 3 months of discontinuation. This will require follow‑up notes, skin assessment scoring or photographic comparisons, and clear medication cessation dates.

5. For smoking (s9(4) and Schedule 1):

   • Obtain a smoking history that quantifies cigarettes per day and duration in years, enabling calculation of pack‑years according to the Schedule (pack‑years = (cigarettes per day ÷ 20) × years smoked).
   • Demonstrate that smoking had not ceased before the clinical onset or clinical worsening. Medical notes, social history entries, or contemporaneous statements can evidence ongoing smoking. If a claimant stopped smoking before onset, do not rely on this factor.
   • Ensure the cumulative exposure meets or exceeds 10 pack‑years.

6. For inability to obtain appropriate clinical management (s9(5)):

   • Collate evidence of barriers such as referral delays, service access limitations, appointment rejections, geographical isolation, or documented waiting lists. Include correspondence with health providers, triage notes, or official communication demonstrating access denial or delay.
   • Have treating clinicians describe what would constitute "appropriate clinical management" for DLE in the claimant’s clinical circumstances and explain how the lack of it plausibly led to clinical worsening.

7. For death from DLE (s7(4); Schedule 1):

   • For a death claim, produce medical certification and clinical records that link the DLE to the terminal event. Obtain cause of death documentation and treating clinician opinions that DLE contributed to the proximate or ultimate cause of death.
   • Use the Schedule’s terminal event examples as a guide, and secure expert evidence linking DLE pathophysiology to the identified terminal event.

8. Link factors to relevant service (s10(1)):

   • Provide evidence that the qualifying factor is related to the claimant’s relevant service period or activities , for example, proof of occupational sun exposure during service for a UV claim, or record of medication administered as part of service‑related treatment.
   • For clinical worsening where the disease pre‑existed, ensure evidence shows DLE was suffered or contracted before or during service but did not arise out of service, because s10(2) limits the clinical worsening application to those circumstances.

9. Address cross‑referenced SoPs if applicable (s11):

   • If a factor depends on an injury/disease that has its own SoP, obtain and apply the current SoP for that condition and conform evidence to its terms. Be alert that those SoPs may change over time as s11 applies them "as in force from time to time".

10. Prepare expert medico‑legal opinions aligned to the SoP:

    • Ask experts to frame opinions explicitly in terms of the SoP’s factors and the balance of probabilities standard referenced in s8. Experts should say whether the factor(s) listed in s9 are present and whether they are related to relevant service.
    • Where improvement after medication cessation is a requirement, ask the expert to document timelines and objective measures of improvement within the 3‑month window (s9(3)).

11. Documentary hygiene and record sequencing:

    • Time‑stamp every document where possible and keep contemporaneous records. Because the SoP hinges on specific timing windows (24 hours to 30 days, 3 days of treatment before onset, 3 months for improvement, pack‑year calculations), precise dates and sequence are critical.

12. Anticipate contested definitions:

    • Be prepared to defend that the clinical presentation matches the statutory definition and that excluded subtypes do not apply (s7(2)). Use specialist dermatology input to map clinical findings to the statute.

Following these steps will align evidence gathering and presentation to the precise thresholds set out in the SoP and to the requirement that any established factor be related to relevant service (s10(1)). The SoP’s evidentiary demands are technical; practitioners should ensure medical evidence is tailored to the statutory language rather than general clinical statements.